Most Recent
No scope in Patents Act for holding directors jointly liable for unjustified threats: court
A letter by King & Wood Mallesons was an unjustifiable threat of patent litigation against car accessories company Clearview, as was an announcement by the firm's client MSA, but MSA's director cannot be held liable as a joint tortfeasor under the Patents Act, a judge has found.
Qld tech firm denies using confidential info for battery patent applications
Queensland technology company Anteotech has hit back at a lawsuit claiming it misused Ferroglobe’s confidential silicon samples in a patent application after a failed collaboration, saying the global speciality metals producer acquiesced to the use. 
Lights out on Hanhwa’s solar cell patent infringement suit
A solar cell patent at the heart of intellectual property litigation brought by South Korean technology giant Hanwha has been found invalid.
Novartis can’t have separate trial on blood pressure drug invalidity claim
Novartis has lost its bid to have Pharmacor’s claim that its patent for a blood pressure drug is invalid decided ahead of a main trial where the Swiss pharmaceutical giant will allege the generic drug maker is threatening to infringe its patent. 
Ferroglobe accuses ASX company of using confidential IP after failed collaboration
Ferroglobe has claimed a Queensland technology company used its confidential information in new patent applications, as the global specialty metals producer races to protect its IP before the applications are published.
Novartis, Pharmacor resolve suit over Gilenya patents
Novartis and and generic drug maker Pharmacor have resolved litigation over the Swiss pharmaceutical giant's patents for blockbuster MS drug Gilenya.
No whey: IP Australia sides with Fonterra in rejecting protein patent
IP Australia has rejected the patent application of Scandinavian dairy giant Arla Foods amba, finding its high-protein whey-based yoghurt invention lacked an inventive step.
Pfizer sues drug companies over Enbrel biosimilar
Pharmaceutical giant Pfizer has fired off a lawsuit against four drug companies for allegedly infringing one of its patents for biologic Enbrel by selling a biosimilar of the blockbuster arthritis drug in Australia.
Novartis can’t appeal loss of experts in MS drug patent feud with Pharmacor
The Full Federal Court won't give Swiss pharmaceuticals giant Novartis the chance to appeal a ruling that threw out three of its four experts in a patent case against generic drug maker Pharmacor.
Novartis challenges loss of experts in spat with Pharmacor over generic Gilenya
Novartis wants to appeal a ruling in its dispute with generic drug maker Pharmacor over patents for its multiple sclerosis drug Gilenya that tossed three of its four experts out of an upcoming so-called hot tub.